Jeremy Abramson, MD, from the Massachusetts General Hospital, Massachusetts, MA discusses the highlights of the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL. Dr Abramson focuses on the negative presented at ASH 2015, in particular the Pyramid clinical trial that assessed the addition of bortozemib to R-CHOP in diffuse large cell lymphoma (DLBCL), the CALGB-50403 study of bortozemib following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell lymphoma (MCL), and the Lumiere trial of alisertib in relapsed/refractory peripheral T-cell lymphoma (PTCL).